Cancer Chemotherapy and Pharmacology

, Volume 34, Issue 6, pp 509–514 | Cite as

Sequential therapy with dacarbazine and carmustine: a phase I study

  • R. Brian Mitchell
  • M. Eileen Dolan
  • Linda Janisch
  • Nicholas J. Vogelzang
  • Mark J. Ratain
  • Richard L. Schilsky
Original Articles Alkyltransferase, Nitrosourea, Dacarbazine, Carmustine, Phase I

Abstract

Depletion of the DNA-repair proteinO6-alkylguanine-DNA alkyltransferase (AGT) increases the sensitivity of cells in culture and of human tumor xenografts to chloroethylnitrosoureas such as carmustine (BCNU). We have previously demonstrated that dacarbazine (DTIC) can deplete AGT activity in cells in culture and in human tumor xenografts. A phase I trial of DTIC followed immediately by BCNU was conducted to determine the DTIC dose resulting in maximal depletion of AGT in the peripheral blood mononuclear cells (PBMC) of cancer patients and to determine the maximally tolerated dose of DTIC given as a 4-h infusion immediately prior to a fixed dose of BCNU. A 4-h infusion of DTIC followed by a 2-h infusion of BCNU was given to 42 patients with refractory solid tumors. Complete depletion of AGT activity was not achieved at DTIC doses of up to 750 mg/m2. The dose-limiting toxicity was hematologic, although at higher doses of BCNU (≥100 mg/m2) we observed significant nonhematologic toxicity. Our recommended phase II doses are 1,000 mg/m2 DTIC followed by 75 mg/m2 BCNU. AGT activity in PBMC of the 28 patients studied decreased to a mean of 62%±11% (SE) of the baseline value at 4 h after initiation of the DTIC infusion. At 24 h after initiation of the DTIC infusion, AGT activity in PBMC was depleted to a mean of 65%±14% of the baseline value. There was no direct correlation between the DTIC dose and the extent of AGT depletion. Baseline PBMC AGT levels varied widely among patients.

Key words

Alkyltransferase Nitrosourea Dacarbazine Carmustine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248Google Scholar
  2. 2.
    Brent TP (1984) Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. Cancer Res 44:1887Google Scholar
  3. 3.
    Dolan ME, Young GS, Pegg AE (1986) Effect ofO 6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res 46:4500Google Scholar
  4. 4.
    Dolan ME, Moschel RC, Pegg AE (1990) Depletion of mammalianO 6-alkylguanine-DNA alkyltransferase activity byO 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87:5368Google Scholar
  5. 5.
    Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE (1990) Modulation of mammalianO 6-alkylguanine-DNA alkyltransferase in vivo byO 6-benzylguanine and its effect of the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun 2:371Google Scholar
  6. 6.
    Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE (1991) Effect ofO 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51:3367Google Scholar
  7. 7.
    Dolan ME, Pegg AE, Biser ND, Moschel RC, English HF (1993) Effect ofO 6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol 32:221Google Scholar
  8. 8.
    Dolan ME, Pegg AE, Moschel RC, Grindey GB (1993) Effect ofO 6-benzylguanine analogs on the sensitivity of human colon tumor xenografts to BCNU. Biochem Pharmacol 46:285Google Scholar
  9. 9.
    Domoradzki J, Pegg AE, Dolan ME, Maher VM, McCormick JJ (1984) Correlation betweenO 6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect ofN-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 5:1641Google Scholar
  10. 10.
    Erickson LC, Bradley MO, Ducore JM, Ewig RAG, Kohn KW (1980) DNA cross-linking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc Natl Acad Sci USA 77:467Google Scholar
  11. 11.
    Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C (1993) Treatment of subcutaneous and intracranial brain tumor xenografts withO 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32:471Google Scholar
  12. 12.
    Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, et al (1992) Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 84:1926Google Scholar
  13. 13.
    Futscher BW, Micetich KC, Barnes DM, Fisher RI, Erickson LC (1989) Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun 1:65Google Scholar
  14. 14.
    Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, et al (1993) Activity and unexpected lung toxicity of the sequential administration of two alkylating agents — dacarbazine and fotemustine — in patients with melanoma. Eur J Cancer 29A:711Google Scholar
  15. 15.
    Gerson SL (1989) Modulation of human lymphocyteO 6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo. Cancer Res 49:3134Google Scholar
  16. 16.
    Gerson SL, Trey JE, Miller K (1988) Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation ofO 6-alkylguanine-DNA alkyltransferase. Cancer Res 48:1521Google Scholar
  17. 17.
    Gerson SL, Zborowski AE, Norton K, Gordon NH, Willson JKV (1993) Synergistic efficacy ofO 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol 45:483Google Scholar
  18. 18.
    Gonzaga PE, Potter PM, Rafferty JA, Niu T, Margison GM, Ludlum DB, et al (1992) Structure of the guanine-cysteine linkage formed between BCNU-treated DNA and humanO 6-methylguanine-DNA methyltransferase. Proc Am Assoc Cancer Res 33:548Google Scholar
  19. 19.
    Karran P (1985) Possible depletion of a DNA repair enzyme in human lymphoma cells by subversive repair. Proc Natl Acad Sci USA 82:5285Google Scholar
  20. 20.
    Kohn KW (1977) Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourca and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res 42:1450Google Scholar
  21. 21.
    Lee DM, Thatcher N, Margison GP (1991)O 6-Alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 51:619Google Scholar
  22. 22.
    Lee SM, Thatcher N, Dougal M, Margison GP (1993) Dosage and cycle effects of dacarbazine (DTIC) and fotemustine onO 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67:216Google Scholar
  23. 23.
    Mastrangelo MJ, Bellet RE, Kane MJ, Berd D (1992) Chemotherapy of melanoma. In: Perry MC (ed) The chemotherapy source book. Williams and Wilkins, Baltimore, p 886Google Scholar
  24. 24.
    Meer L, Schold SC, Kleihues P (1989) Inhibition of the hepaticO 6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. Biochem Pharmacol 38:929Google Scholar
  25. 25.
    Micetich KC, Futscher B, Koch D, Fisher RI, Erickson LC (1992) Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst 84:256Google Scholar
  26. 26.
    Mitchell EP, Schein PS (1992) Nitrosoureas. In: Perry MC (ed) The chemotherapy source book, Williams and Wilkins, Baltimore, p 384Google Scholar
  27. 27.
    Mitchell RB, Dolan ME (1993) Effect of temozolomide and dacarbazine onO 6-alkylguanine-DNA-alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32:59Google Scholar
  28. 28.
    Mitchell RB, Moschel RC, Dolan ME (1992) Effect ofO 6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand crosslink formation. Cancer Res 52:1171Google Scholar
  29. 29.
    Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, et al (1992) Modulation ofO 6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res 52:2456Google Scholar
  30. 30.
    Pegg AE (1990) MammalianO 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenesis and therapeutic agents. Cancer Res 50:6119Google Scholar
  31. 31.
    Pegg AE, Wiest L, Mummert C, Stine L, Moschel RC, Dolan ME (1991) Use of antibodies to humanO 6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated withO 6-benzylguanine orN-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 12:1679Google Scholar
  32. 32.
    Pieper RO, Futscher BW, Dong Q, Erickson LC (1991) Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy onO 6-methylguanine DNA methyltransferse activity and mRNA levels in HT-29 cells in vitro. Cancer Res 51:1581Google Scholar
  33. 33.
    Robins P, Harris AL, Goldsmith I, Lindahl T (1983) Cross-linking of DNA induced by chloroethylnitrosourea in prevented byO 6-methylguanine-DNA methyltransferase. Nucleic Acids Res 11:7743Google Scholar
  34. 34.
    Skipper HE (1974) Combination therapy: some concepts and results. Cancer Chemother Rep 4:137Google Scholar
  35. 35.
    Yarosh DB, Hurst-Calderone S, Babich MA, Day RS (1986) Inactivation ofO 6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea byO 6-methylguanine as a free base. Cancer Res 46:1663Google Scholar
  36. 36.
    Zeller WJ, Berger MR, Weber E (1986) More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat. Cancer Res 46:1714Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • R. Brian Mitchell
    • 1
    • 2
  • M. Eileen Dolan
    • 1
    • 2
  • Linda Janisch
    • 1
    • 2
  • Nicholas J. Vogelzang
    • 1
    • 2
  • Mark J. Ratain
    • 1
    • 2
  • Richard L. Schilsky
    • 1
    • 2
  1. 1.Section of Hematology/Oncology, Department of Medicine, Cancer Research CenterThe University of ChicagoChicagoUSA
  2. 2.Committee on Clinical PharmacologyThe University of ChicagoChicagoUSA

Personalised recommendations